PMID- 32377537
OWN - NLM
STAT- MEDLINE
DCOM- 20210219
LR  - 20220414
IS  - 2314-7156 (Electronic)
IS  - 2314-8861 (Print)
IS  - 2314-7156 (Linking)
VI  - 2020
DP  - 2020
TI  - Gaps in Study Design for Immune Parameter Research for Latent Tuberculosis 
      Infection: A Systematic Review.
PG  - 8074183
LID - 10.1155/2020/8074183 [doi]
LID - 8074183
AB  - BACKGROUND: Immune parameters (IP) have been extensively studied to distinguish 
      between latent tuberculosis (LTBI) and active tuberculosis (TB). OBJECTIVE: To 
      determine the IP associated with LTBI, compared to active TB and individuals not 
      infected by M. tuberculosis published in literature. METHODS: We conducted a 
      systematic search using Google Scholar and PubMed databases, combining the MeSH 
      terms latent tuberculosis, Mycobacterium tuberculosis, cytokines, and biological 
      markers, with the free terms, biomarkers and cytokines. Spanish, English, and 
      Portuguese articles comparing the concentration of IP associated with LTBI, 
      either in plasma/serum or in vitro, in adults and nonimmunocompromised versus 
      individuals with TB or without M. tuberculosis infection between 2006 July and 
      2018 July were included. Two blinded reviewers carried out the searches, read the 
      abstracts, and selected the articles for analysis. Participants' information, 
      diagnostic criteria, IP, detection methods, and biases were collected. RESULTS: 
      We analyzed 36 articles (of 637 abstracts) with 93 different biomarkers in 
      different samples. We found 24 parameters that were increased only in active TB 
      (TGF-alpha, CSF3, CSF2, CCL1 [I-309], IL-7, TGF-beta1, CCL3 [MIP-1alpha], sIL-2R, TNF-beta, 
      CCL7 [MCP-3], IFN-alpha, fractalkine, I-TAG, CCL8 [MCP-2], CCL21 [6Ckine], PDGF, 
      IL-22, VEGF-A, LXA4, PGE2, PGF2alpha, sCD163, sCD14, and 15-Epi-LXA4), five were 
      elevated in LTBI (IL-5, IL-17F, IL-1, CCL20 [MIP-3alpha], and ICAM-1), and two 
      substances were increased among uninfected individuals (IL-23 and basic FGF). We 
      found high heterogeneity between studies including failure to account for the 
      time/illness of the individuals studied; varied samples and protocols; different 
      clinical classification of TB; different laboratory methods for IP detection, 
      which in turn leads to variable units of measurement and assay sensitivities; and 
      selection bias regarding TST and booster effect. None of the studies adjusted the 
      analysis for the effect of ethnicity. CONCLUSIONS: It is mandatory to harmonize 
      the study of immune parameters for LTBI diagnosis. This systematic review is 
      registered with PROSPERO CRD42017073289.
CI  - Copyright (c) 2020 Mariana Herrera et al.
FAU - Herrera, Mariana
AU  - Herrera M
AUID- ORCID: 0000-0002-7482-2010
AD  - Grupo de Epidemiologia, Facultad Nacional de Salud Publica, Universidad de 
      Antioquia, Medellin, Colombia.
AD  - Grupo de Investigacion en Salud Publica, Universidad Pontificia Bolivariana, 
      Medellin, Colombia.
FAU - Vera, Cristian
AU  - Vera C
AUID- ORCID: 0000-0001-6775-151X
AD  - Grupo de Investigacion en Salud Publica, Universidad Pontificia Bolivariana, 
      Medellin, Colombia.
AD  - Clinica Universitaria Bolivariana, Universidad Pontificia Bolivariana, Medellin, 
      Colombia.
FAU - Keynan, Yoav
AU  - Keynan Y
AUID- ORCID: 0000-0003-4948-4707
AD  - Departments of Internal Medicine, Medical Microbiology & Infectious Diseases and 
      Community Health Sciences, University of Manitoba, Winnipeg, Canada.
FAU - Rueda, Zulma Vanessa
AU  - Rueda ZV
AUID- ORCID: 0000-0001-6342-1812
AD  - Grupo de Investigacion en Salud Publica, Universidad Pontificia Bolivariana, 
      Medellin, Colombia.
AD  - Facultad de Medicina, Universidad Pontificia Bolivariana, Medellin, Colombia.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20200421
PL  - Egypt
TA  - J Immunol Res
JT  - Journal of immunology research
JID - 101627166
RN  - 0 (Antigens, CD)
RN  - 0 (Biomarkers)
RN  - 0 (Cytokines)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
SB  - IM
MH  - Antigens, CD/metabolism
MH  - Biomarkers
MH  - Cytokines/metabolism
MH  - Diagnosis, Differential
MH  - Disease Progression
MH  - Humans
MH  - Intercellular Signaling Peptides and Proteins/metabolism
MH  - Latent Tuberculosis/*diagnosis/immunology
MH  - Mycobacterium tuberculosis/*physiology
PMC - PMC7191376
COIS- The authors declare that they have no competing of interests.
EDAT- 2020/05/08 06:00
MHDA- 2021/02/20 06:00
PMCR- 2020/04/21
CRDT- 2020/05/08 06:00
PHST- 2019/11/10 00:00 [received]
PHST- 2020/03/16 00:00 [accepted]
PHST- 2020/05/08 06:00 [entrez]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
PHST- 2020/04/21 00:00 [pmc-release]
AID - 10.1155/2020/8074183 [doi]
PST - epublish
SO  - J Immunol Res. 2020 Apr 21;2020:8074183. doi: 10.1155/2020/8074183. eCollection 
      2020.